Biallelic inactivation of TP53, occurring in 2–4% of newly diagnosed MM patients, was identified as an ultra-high-risk feature of MM, being associated with a median survival of less than 2 years [Ashby et al., 2019; Munawar et al., 2019]. Here, TP53 is linked to Miyoshi myopathy.